Audentes Therapeutics and Three More Stocks Under Scanner in the Biotech Space
Stock Research Monitor: AVEO, CLDX, and CERS
LONDON, UK / ACCESSWIRE / May 18, 2018 / If you want a free Stock Review on AVEO, CLDX, and CERS sign up now at www.wallstequities.com/registration. On Thursday, May 17, 2018, the NASDAQ Composite ended the trading session at 7,382.47, down 0.21%; the Dow Jones Industrial Average edged 0.22% lower, to finish at 24,713.98; and the S&P 500 closed at 2,720.13, slightly dropping 0.09%. US markets saw four out of nine sectors finishing the day in red, four in green, and one in neutral territory. This Friday, WallStEquities.com has initiated reports coverage on the following Biotechnology equities: Audentes Therapeutics Inc. (NASDAQ: BOLD), AVEO Pharmaceuticals Inc. (NASDAQ: AVEO), Celldex Therapeutics Inc. (NASDAQ: CLDX), and Cerus Corp. (NASDAQ: CERS). All you have to do is sign up today for this free limited time offer by clicking the link below.
www.wallstequities.com/registration
Audentes Therapeutics
San Francisco, California headquartered Audentes Therapeutics Inc.'s stock finished Thursday's session 21.91% higher at $41.39 with a total trading volume of 1.88 million shares, which is above its three months average volume of 366.72 thousand shares. The Company's shares have advanced 20.71% in the previous three months and 167.20% over the past twelve months. The stock is trading above its 50-day and 200-day moving averages by 22.04% and 39.76%, respectively. Additionally, shares of Audentes Therapeutics, which focuses on developing and commercializing gene therapy products for patients suffering from diseases caused by single gene defects, have a Relative Strength Index (RSI) of 65.03. Get the full research report on BOLD for free by clicking below at:
www.wallstequities.com/registration/?symbol=BOLD
AVEO Pharmaceuticals
On Thursday, shares in Cambridge, Massachusetts-based AVEO Pharmaceuticals Inc. recorded a trading volume of 1.26 million shares. The stock ended the session 2.29% lower at $2.13. The Company's shares have advanced 243.55% over the last twelve months. The stock is trading below its 50-day moving average by 19.20%. Moreover, shares of AVEO Pharma, which develops and commercializes a portfolio of targeted medicines for oncology and other areas of unmet medical need, have an RSI of 33.99. Get access to our top-rated research, including the free report on AVEO at:
www.wallstequities.com/registration/?symbol=AVEO
Celldex Therapeutics
Hampton, New Jersey headquartered Celldex Therapeutics Inc.'s shares closed the day 0.62% lower at $0.69. The stock recorded a trading volume of 1.79 million shares. The stock is trading below its 50-day moving average by 57.08%. Additionally, shares of Celldex Therapeutics, which focuses on the development and commercialization of various immunotherapy technologies and other cancer-targeting biologics, have an RSI of 23.28. Click here to subscribe for a free membership which welcomes you with our report on CLDX at:
www.wallstequities.com/registration/?symbol=CLDX
Cerus
Shares in Concord, California headquartered Cerus Corp. finished 1.56% higher at $6.51. The stock recorded a trading volume of 674,621 shares. The Company's shares have advanced 15.43% in the last month, 58.01% in the previous three months, and 112.40% over the last twelve months. The stock is trading above its 50-day and 200-day moving averages by 18.43% and 66.08%, respectively. Furthermore, shares of Cerus, which focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety, have an RSI of 69.26. Join our big investor community at Wall St. Equities today and get your free report on CERS at:
www.wallstequities.com/registration/?symbol=CERS
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@wallstequities.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
https://wallstequities.com/legal-disclaimer/
CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: info@wallstequities.com
Phone number: 21 32 044 483
Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: Wall St. Equities
